Growth & profitability
- Revenue has declined 39.7% per year over the past 4 years.
Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 3.3 years of cash runway.
NAMS Financials Newamsterdam Pharma Co N.V.
5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $23M | -$203M | 0.0% | -1002.9% | -$148M | — | $490M |
| 2024 | $46M | -$242M | 0.0% | -386.9% | -$159M | — | $772M |
| 2023 | $14M | -$177M | 0.0% | -1298.6% | -$141M | — | $340M |
| 2022 | $103M | -$23M | 0.0% | -3.5% | $10M | — | — |
| 2021 | — | -$42M | — | — | -$30M | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $3M | -$48M | 0.0% | -1921.7% | -$31M | — | $458M |
| Dec '25 | $32000 | -$75M | 0.0% | -206187.5% | -$41M | — | $490M |
| Sep '25 | $348000 | -$72M | 0.0% | -15845.7% | -$33M | — | $538M |
| Jun '25 | $19M | -$17M | 0.0% | -186.1% | -$38M | — | $564M |
| Mar '25 | $3M | -$40M | 0.0% | -2314.5% | -$36M | — | $748M |
| Dec '24 | $13M | -$92M | 0.0% | -338.5% | -$37M | — | $772M |
| Sep '24 | $29M | -$17M | 0.0% | -85.9% | -$13M | — | $423M |
| Jun '24 | $2M | -$39M | 0.0% | -2306.9% | -$54M | — | — |
| Mar '24 | $1M | -$94M | 0.0% | -3960.2% | -$55M | — | — |
| Dec '23 | $803000 | -$49M | 0.0% | -6360.4% | -$33M | — | $340M |
| Sep '23 | $3M | -$47M | 0.0% | -1685.1% | -$47M | — | — |
| Jun '23 | $2M | -$38M | 0.0% | -2474.2% | -$29M | — | — |
| Mar '23 | $9M | -$42M | 0.0% | -461.8% | -$32M | — | — |
Valuation over time
How the market has priced NAMS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 15.3× (Mar '23) to 167.0× (Jun '26).
P/S
Frequently asked questions
Is NAMS growing its revenue and profit?
Over the past 4 years, Newamsterdam Pharma Co N.V.'s revenue has declined 39.7% per year. These are computed facts, not advice.
How much debt does NAMS have?
As of FY2025, Newamsterdam Pharma Co N.V. reported — of total debt against $490M of cash.
What is NAMS's profit margin?
In FY2025, gross margin was —, operating margin -1002.9%, and net margin -902.1%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.